1. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The lancet Respiratory medicine. 2017 Apr 30;5(4):291-360.
  2. Ryerson, C. J., Corte, T. J., Lee, J. S., Richeldi, L., Walsh, S. L., Myers, J. L., Udwadia Z.F., ... & Lederer, D. J. (2017). A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease: An International Working Group Perspective. American Journal of Respiratory And Critical Care Medicine, (ja).
  3. Chawla PK, Lokhande RV, Naik PR, Dherai AJ, Amale RA, UdwadiaZF, Mahashur AA, Soman R, Ashavaid TF. Failure to reach therapeutic levels of rifampicin and isoniazid by recommended dosages. Infectious Diseases. 2017 Feb 16:1-4.
  4. Udwadia ZF, Ganatra S, Mullerpattan JB. Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India. European Respiratory Journal. 2017 Mar 1;49(3):1601699.
  5. Udwadia ZF, Richeldi L. Interstitial Lung Disease in India. Keep Searching and You’ll Keep Finding. Am J Resp Crit Care Med 2017;714-715.
  6. Ganatra S, Udwadia ZF, Rodrigues C. Therapeutic choices in rifampicin-resistant tuberculosis. The Lancet Infectious Diseases. 2016 Nov 1;16(11):1220.
  7. Mobility patterns of persons at risk for drug-resistant tuberculosis in Mumbai, India. Conners E, Garfein RS, Rodwell TC, Udwadia ZF, Catanzaro DG. Int J Tuberc Lung Dis. 2016 Dec;20(12):1633-1638. ​PMID:27931339
  8. Importance of Therupeutic Drug Monitoring of Rifampicin. Chawla PK, ​Udwadia ZF, Soman RN, Mahashur AA, Amale RA, Dheral AJ, ​Lokhande RV, Naik PR, Ashawaid TF, J Assoc Physician India 2016 Aug ​64 Aug 64 Aug 64 L64-72) ​​PMID:27762112
  9. Who will teach the teachers: An analysis of the inhaler technique of ​Indian patients and health care providers in a tertiary health care ​centre. Mullerpattan JB, Udwadia ZZ, Kathar SS, Shah HD, Rastogi SA, ​Pandey KV, Udwadia ZF. Lung India. 2016 Sep-Oct;33(5):493-5. doi: ​10.4103/0970-2113.188962.
  10. Possible impact of the standardized Category IV regimen on multidrug-​resistant tuberculosis patients in Mumbai. Udwadia ZF, Mullerpattan ​JB, Shah KD, Rodrigues CS.Lung India 2016 May-Jun; 3.3(3):253-6, ​doi:10.4.103/0970-2113.180800 ​PMID : 27185987
  11. BCG and New Preventive Tuberculosis Vaccines: Implications for ​Healthcare WorkersHatherill M, Scriba TJ, Udwadia ZF, Mullerpattan​JB, Hawkridge A, Mahomed H, Dye C. Clin Infect Dis. 2016 May 15:62 ​Suppl ​3:S262-7. Doi:10.1093/cid/ciwi025 ​PMID :27118856